Online inquiry

IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1035MR)

This product GTTS-WQ1035MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1035MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2353MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ10490MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ10655MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ61MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ16006MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ15841MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ3755MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ9257MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW